FAST PML/RARα(RARA) Translocation, Dual Fusion
- PML, 15q24.1, Red
- RARα, 17q21.1-q21.2, Green
The PML probe mix, labelled in red, consists of a 151kb probe centromeric to the PML gene and a 174kb probe telomeric to the PML gene. The RARα probe mix, labelled in green, consists of a 167kb probe centromeric to the RARα (RARA) gene, including the CASC3 gene, and a 164kb probe, including the telomeric end of the RARα gene as well as the TOP2A and IGFBP4 genes.
Immediate treatment of patients carrying the t(15;17) (PML/RARA) translocation is critical due to the risk of early death2. This FAST PML/RARA FISH probe allows rapid detection of the rearrangement, with only one hour of hybridisation required.
The fusion gene PML/RARA is created by the t(15;17)(q24.1;q21.2) translocation, found in 98% of AML M3 Acute hypergranular promyelocytic leukaemia and 9% of AML overall1,2,3. The PML protein is a transcription factor and RARA encodes a nuclear receptor. The fusion protein generated, PML-RARA, is a chimaeric transcription factor that operates as a dominant negative form of RARA and results in cells that are blocked at the promyelocytic stage of differentiation and then proliferate. Gain of function mutation allows repression of multiple genes and recruitment of DNA methyltransferases to promoters, allowing prolonged suppression. PML-RARA also activates components of the WNT signalling pathway, promoting stem cell renewal.
Immediate treatment of PML/RARA positive patients is critical as intravascular coagulation causes early death in 10-40% of cases2. Terminal differentiation is induced by the use of all-trans-retinoic-acid (ATRA), which reactivates the RARA gene and degrades the PML-RARA fusion product and 80-90% of treated patients achieve complete remission1,2,4. Despite the efficacy of ATRA, the death rate remains around 15-20%, but 70% of patients will achieve 3 year survival2. Additional abnormalities found with PML/RARA translocations include trisomy 8, seen in one third of cases, del(7q) and del(9q)2.
I am grateful for the excellent products I receive from Cytocell at a reasonable price, but more importantly the superb customer support. The speed in which I receive answers or suggestions makes my life as a director much easier and allows me to focus on patient care. The quality and consistency of Cytocell’s probes means I can trust the results, and my clients get their results in a timely manner. Dr. Theresa C. Brown, Director, Cytogenetics Laboratory, Hayward Genetics Center, Tulane University School of Medicine
1. Licht, Sternberg, The Molecular Pathway of AML ASH Education Book 2005;137-42
2. Huret and Chomienne. t(15;17)(q24;q21). Atlas Genet Cytogenet Oncol Haematol 1998;2(3):329-34
3. Heim and Mitelman, Willey-Liss, Inc. 1995
4. Greaves, BMJ 2002;324(7332):283-7
- Area of Interest*
- AML, APL
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.